Cannabioids as a New Intervention for Amphetamine Dependence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder.

The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Marijuana Drug Discrimination and Self-Administration

NCT00943930

Marijuana Abuse

COMPLETED

Activation of the Endocannabinoid System and Cognition

NCT05226351

Post Traumatic Stress Disorder

COMPLETED NA

Dose-response of Cannabis and Driving

NCT03656029

Driving Impaired Cognitive Impairment Abuse Cannabis

COMPLETED PHASE2

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

NCT02094599

Drug Abuse, Medication

COMPLETED PHASE1

Cannabis Edibles and Simulated Driving

NCT06595576

Cannabis Driving Under the Influence

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amphetamine Addiction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

* Current DSM-V criteria for amphetamine use disorder
* Ability to give valid, informed consent

Exclusion Criteria

* Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician.
* Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality
* Any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No